34 related articles for article (PubMed ID: 38548404)
1. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Stelljes M; Middeke JM; Bug G; Wagner-Drouet EM; Müller LP; Schmid C; Krause SW; Bethge W; Jost E; Platzbecker U; Klein SA; Schubert J; Niederland J; Kaufmann M; Schäfer-Eckart K; Schaich M; Baldauf H; Stölzel F; Petzold C; Röllig C; Alakel N; Steffen B; Hauptrock B; Schliemann C; Sockel K; Lang F; Kriege O; Schaffrath J; Reicherts C; Berdel WE; Serve H; Ehninger G; Schmidt AH; Bornhäuser M; Mikesch JH; Schetelig J;
Lancet Haematol; 2024 May; 11(5):e324-e335. PubMed ID: 38583455
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Garcia JS; Kim HT; Murdock HM; Ansuinelli M; Brock J; Cutler CS; Gooptu M; Ho VT; Koreth J; Nikiforow S; Romee R; Shapiro R; DeAngelo DJ; Stone RM; Bat-Erdene D; Ryan J; Contreras ME; Fell G; Letai A; Ritz J; Lindsley RC; Soiffer RJ; Antin JH
Blood Adv; 2024 Feb; 8(4):978-990. PubMed ID: 38197938
[TBL] [Abstract][Full Text] [Related]
3. Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Salamero O; Molero A; Pérez-Simón JA; Arnan M; Coll R; Garcia-Avila S; Acuña-Cruz E; Cano I; Somervaille TCP; Gutierrez S; Arévalo MI; Xaus J; Buesa C; Limón A; Faller DV; Bosch F; Montesinos P
Lancet Haematol; 2024 May; ():. PubMed ID: 38824932
[TBL] [Abstract][Full Text] [Related]
4. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Tiong IS; Hiwase DK; Abro E; Bajel A; Palfreyman E; Beligaswatte A; Reynolds J; Anstee N; Nguyen T; Loo S; Chua CC; Ashby M; Wiltshire KM; Fleming S; Fong CY; Teh TC; Blombery P; Dillon R; Ivey A; Wei AH
J Clin Oncol; 2024 Jun; 42(18):2161-2173. PubMed ID: 38427924
[TBL] [Abstract][Full Text] [Related]
5. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
Kobayashi T; Sato H; Miura M; Fukushi Y; Kuroki W; Ito F; Teshima K; Watanabe A; Fujishima N; Kobayashi I; Kameoka Y; Takahashi N
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782790
[TBL] [Abstract][Full Text] [Related]
6. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
Garcia-Manero G; Kazmierczak M; Wierzbowska A; Fong CY; Keng MK; Ballinari G; Scarci F; Adès L
Leuk Res; 2024 May; 140():107480. PubMed ID: 38499457
[TBL] [Abstract][Full Text] [Related]
7. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Senapati J; Kantarjian HM; Bazinet A; Reville P; Short NJ; Daver N; Borthakur G; Bataller A; Jabbour E; DiNardo C; Haddad F; Sasaki K; Popat U; Oran B; Alousi AM; Loghavi S; Shpall E; Garcia-Manero G; Ravandi F; Kadia TM
Cancer; 2024 May; ():. PubMed ID: 38809547
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of older patients with acute myelogenous leukaemia without allogenic stem cell transplantation at Akershus University Hospital].
Storlien T; Dahm AEA
Tidsskr Nor Laegeforen; 2023 Oct; 143(15):. PubMed ID: 37874067
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.
Guest EM; Kairalla JA; Devidas M; Hibbitts E; Carroll AJ; Heerema NA; Kubaney HR; August MA; Ramesh S; Yoo B; Farooqi MS; Pauly MG; Wechsler DS; Miles RR; Reid JM; Kihei CD; Gore L; Raetz EA; Hunger SP; Loh ML; Brown PA
Haematologica; 2024 Jun; ():. PubMed ID: 38867582
[TBL] [Abstract][Full Text] [Related]
10. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Ivanov V; Yeh SP; Mayer J; Saini L; Unal A; Boyiadzis M; Hoffman DM; Kang K; Addo SN; Mendes WL; Fathi AT
Future Oncol; 2022 Aug; 18(26):2879-2889. PubMed ID: 35852098
[TBL] [Abstract][Full Text] [Related]
11. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox W; Grimm S; Howick J; Armstrong N; Ahmadu C; McDermott K; Otten T; Noake C; Wolff R; Joore M
Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
[TBL] [Abstract][Full Text] [Related]
13. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
15. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]